US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

CITIUS ONCOLOGY INC

0.6600

+0.03906.28%

Volume:39.43K

Turnover:25.64K

Market Cap:47.22M

PE:-1.98

High:0.6719

Open:0.6307

Low:0.6307

Close:0.6210

Loading ...

Overview Company News Filings

Wall Street Set to Open Lower Monday as Investors Gird for More Tariffs, Await Key Manufacturing Data

MT Newswires Live

Investors Brace for 'Liberation Day' as US Futures Trend Sharply Lower in Monday's Premarket

MT Newswires Live

Citius Oncology Q1 2025 GAAP EPS $(1.30) Misses $(0.06) Estimate

Press Release: Citius Oncology, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update

Citius Pharmaceuticals and Citius Oncology announce J-Code issued for Lymphir

Citius Pharmaceuticals and Citius Oncology Announce Unique Permanent J-Code Issued for Lymphir by Centers for Medicare and Medicaid Services

THOMSON REUTERS

Citius Pharmaceuticals Inc: Permanent J-Code (J9161) Expected to Be Effective April 1, 2025

THOMSON REUTERS

Citius Pharmaceuticals and Citius Oncology Announce Unique Permanent J-Code Issued for LYMPHIR by Centers for Medicare and Medicaid Services

Citius Pharmaceuticals and Citius Oncology to launch Lymphir in 1H25

Citius Pharmaceuticals and Citius Oncology Highlight Lymphir Commercial Launch Planned for First Half of 2025

THOMSON REUTERS

Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025

Citius Oncology to explore strategic alternatives

Sector Update: Health Care Stocks Decline Late Afternoon

MT Newswires Live

Citius Oncology Retains Jeffries to Consider Strategic Alternatives

MT Newswires Live

Citius Oncology Engages Jefferies as Exclusive Financial Advisor to Explore Strategic Alternatives

THOMSON REUTERS

Citius Oncology Engages Jefferies as Exclusive Financial Advisor to Explore Strategic Alternatives

Citius Pharmaceuticals upgraded to Buy from Hold at D. Boral Capital

Reported Friday, Citius Oncology FY 2024 GAAP EPS $(0.31) Misses $(0.29) Estimate

BRIEF-Citius Oncology Reports Fiscal Full Year 2024 Financial Results And Provides Business Update

Citius Oncology, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/CTOR/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CTOR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CTOR\",,,,,undefined,":{"symbol":"CTOR","market":"US","secType":"STK","nameCN":"CITIUS ONCOLOGY INC","latestPrice":0.66,"timestamp":1745352000000,"preClose":0.621,"halted":0,"volume":39432,"delay":0,"floatShares":5502787,"shares":71552402,"eps":-0.334177,"marketStatus":"Post-Mkt","change":0.039,"latestTime":"04-22 17:03:38 EDT","open":0.6307,"high":0.6719,"low":0.6307,"amount":25635.112106,"amplitude":0.066345,"askPrice":0.67,"askSize":2819,"bidPrice":0.615,"bidSize":900,"shortable":3,"etf":0,"ttmEps":-0.334177,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1745366400000},"marketStatusCode":4,"adr":0,"exchange":"NASDAQ","adjPreClose":0.621,"preHourTrading":{"tag":"盘前","latestPrice":0.6503,"preClose":0.6262,"latestTime":"09:08 EDT","volume":2,"amount":1.3005,"timestamp":1745327317200},"volumeRatio":0.682406},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CTOR\",,,,,undefined,":{"symbol":"CTOR","floatShares":5502787,"roa":"-20.24%","roe":"-72.11%","lyrEps":-0.310765,"volumeRatio":0.682406,"shares":71552402,"dividePrice":0,"high":0.6719,"amplitude":0.066345,"preClose":0.621,"low":0.6307,"week52Low":0.5506,"pbRate":"1.14","week52High":49,"institutionHeld":0,"latestPrice":0.66,"committee":-0.515999,"eps":-0.334177,"divideRate":0,"volume":39432,"delay":0,"ttmEps":-0.334177,"open":0.6307,"prevYearClose":1.15,"prevWeekClose":0.6719,"prevMonthClose":0.93,"prevQuarterClose":0.93,"fiveDayClose":0.6638,"twentyDayClose":0.71,"sixtyDayClose":1.25},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CTOR\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2523787941","title":"Wall Street Set to Open Lower Monday as Investors Gird for More Tariffs, Await Key Manufacturing Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2523787941","media":"MT Newswires Live","labels":["economic"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523787941?lang=en_us&edition=fundamental","pubTime":"2025-03-31 21:02","pubTimestamp":1743426126,"startTime":"0","endTime":"0","summary":"US stocks look set to open lower in Monday's trading session as investors brace for President Donald Trump's \"Liberation Day\" tariff announcements on Wednesday. Key manufacturing data is also set for ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"economic","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4539","HMST","BK4139","BK4091","GATE","BK7084","MWYN","AUID","PCVX","RKT.AU","BK4195","ISBC","RKT","LU0053671581.USD","DIBS","BK4104","BK4190","BK4211","COOP","CTOR","DMN","BK4099","BK4547","BK4122","BK4097","NWTG","BK4220","BK4229","IE0009354923.USD"],"gpt_icon":0},{"id":"2523946582","title":"Investors Brace for 'Liberation Day' as US Futures Trend Sharply Lower in Monday's Premarket","url":"https://stock-news.laohu8.com/highlight/detail?id=2523946582","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523946582?lang=en_us&edition=fundamental","pubTime":"2025-03-31 20:16","pubTimestamp":1743423386,"startTime":"0","endTime":"0","summary":"US stock futures are sharply lower in Monday's premarket activity as investors brace for President Donald Trump's \"Liberation Day\" tariffs announcement Wednesday, and await key manufacturing data comi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4211","CTOR","LU0053671581.USD","BK4122","BK4220","PCVX","ISBC","BK4190","IE0009354923.USD","NWTG","BK4539","DIBS","BK4139","GATE","MWYN","BK4104"],"gpt_icon":0},{"id":"2511561096","title":"Citius Oncology Q1 2025 GAAP EPS $(1.30) Misses $(0.06) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2511561096","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511561096?lang=en_us&edition=fundamental","pubTime":"2025-02-15 05:33","pubTimestamp":1739568832,"startTime":"0","endTime":"0","summary":"Citius Oncology (NASDAQ:CTOR) reported quarterly losses of $(1.30) per share which missed the analyst consensus estimate of $(0.06) by 2066.67 percent.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/02/43749115/citius-oncology-q1-2025-gaap-eps-1-30-misses-0-06-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Citius Oncology Q1 2025 GAAP EPS $(1.30) Misses $(0.06) Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTOR"],"gpt_icon":0},{"id":"2511261061","title":"Press Release: Citius Oncology, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2511261061","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511261061?lang=en_us&edition=fundamental","pubTime":"2025-02-15 05:30","pubTimestamp":1739568600,"startTime":"0","endTime":"0","summary":"CRANFORD, N.J., Feb. 14, 2025 /PRNewswire/ -- Citius Oncology, Inc.  , a specialty biopharmaceutical company focused on the development and commercialization of novel targeted oncology therapies, today reported business and financial results for the fiscal first quarter ended December 31, 2024.Fiscal First Quarter 2025 Business Highlights and Subsequent Developments. -- Engaged Jefferies as exclusive financial advisor to assist in evaluating. strategic alternatives aimed at maximizing shareholder value, with. -- Progressed commercial readiness for the planned launch of LYMPHIR in. the first half of 2025, with key initiatives including:. -- Manufactured sufficient inventory for launch and initial sales. diftitox-cxdl, for intravenous use, 1 microgram) for LYMPHIR,assigned by the Centers for Medicare & Medicaid Services ,with an expected effective date of April 1, 2025;potential as an immuno-oncology combination therapy being conducted at. -- R&D expenses were $1.3 million for the first ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03160","BK4099","LU1894683264.USD","SITC","BK4139","BK4604","CTOR","LU2637428348.USD","BK4208","LU1894683348.USD","TM","BK4585","BK4080","BK4555","BK4588","CMS","LU2346227817.USD","BK4231"],"gpt_icon":0},{"id":"2509713472","title":"Citius Pharmaceuticals and Citius Oncology announce J-Code issued for Lymphir","url":"https://stock-news.laohu8.com/highlight/detail?id=2509713472","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509713472?lang=en_us&edition=fundamental","pubTime":"2025-02-06 22:01","pubTimestamp":1738850467,"startTime":"0","endTime":"0","summary":"Citius Pharmaceuticals (CTXR) and its oncology-focused subsidiary, Citius Oncology (CTOR) announced that Lymphir has been assigned a unique, perman...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/citius-pharmaceuticals-and-citius-oncology-announce-j-code-issued-for-lymphir?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/citius-pharmaceuticals-and-citius-oncology-announce-j-code-issued-for-lymphir?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CTOR","CTXR","BK4007","BK4139"],"gpt_icon":0},{"id":"2509637279","title":"Citius Pharmaceuticals and Citius Oncology Announce Unique Permanent J-Code Issued for Lymphir by Centers for Medicare and Medicaid Services","url":"https://stock-news.laohu8.com/highlight/detail?id=2509637279","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509637279?lang=en_us&edition=fundamental","pubTime":"2025-02-06 21:55","pubTimestamp":1738850132,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250206:nFWN3OX1PD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CTOR","BK4007","BK4139","CTXR"],"gpt_icon":0},{"id":"2509027963","title":"Citius Pharmaceuticals Inc: Permanent J-Code (J9161) Expected to Be Effective April 1, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2509027963","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509027963?lang=en_us&edition=fundamental","pubTime":"2025-02-06 21:55","pubTimestamp":1738850132,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250206:nFWN3OX1PD:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CTOR","CTXR","BK4007","BK4139"],"gpt_icon":0},{"id":"2509027926","title":"Citius Pharmaceuticals and Citius Oncology Announce Unique Permanent J-Code Issued for LYMPHIR by Centers for Medicare and Medicaid Services","url":"https://stock-news.laohu8.com/highlight/detail?id=2509027926","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509027926?lang=en_us&edition=fundamental","pubTime":"2025-02-06 21:55","pubTimestamp":1738850100,"startTime":"0","endTime":"0","summary":"Permanent J-Code  expected to be effective April 1, 2025. LYMPHIR is approved by the U.S. Food and Drug Administration  for the treatment of adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma  after at least one prior systemic therapy.CRANFORD, N.J., Feb. 6, 2025 /PRNewswire/ -- Citius Pharmaceuticals, Inc.   and its oncology-focused subsidiary, Citius Oncology, Inc.  , today announced that LYMPHIR  has been assigned a unique, permanent Healthcare Common Procedure Coding System  J-code  by the Centers for Medicare & Medicaid Services .Effective April 1, 2025, healthcare providers may use the permanent J-code, J9161 , when submitting claims for LYMPHIR.\"The establishment of a permanent J-code marks a critical milestone in supporting patient access to LYMPHIR, providing coding clarity for physicians and facilities who administer LYMPHIR, and facilitating reimbursement. This achievement is a key step in ensuring that LYMPHIR is accessible to patients with com","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/citius-pharmaceuticals-citius-oncology-announce-135500837.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/citius-pharmaceuticals-citius-oncology-announce-135500837.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2346227817.USD","BK4145","LU1894683264.USD","CTXR","BK4139","LU2125910500.SGD","LU2637428348.USD","LU2045819591.USD","BK4526","BK4563","CTOR","BK4588","MF","BK4585","CMS","BK4113","BK4208","BK4539","LU1894683348.USD"],"gpt_icon":1},{"id":"2501620986","title":"Citius Pharmaceuticals and Citius Oncology to launch Lymphir in 1H25","url":"https://stock-news.laohu8.com/highlight/detail?id=2501620986","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501620986?lang=en_us&edition=fundamental","pubTime":"2025-01-07 21:15","pubTimestamp":1736255737,"startTime":"0","endTime":"0","summary":"Citius Pharmaceuticals (CTXR) and its oncology-focused subsidiary, Citius Oncology (CTOR), announced progress in preparations for the commercial la...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/citius-pharmaceuticals-and-citius-oncology-to-launch-lymphir-in-1h25?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/citius-pharmaceuticals-and-citius-oncology-to-launch-lymphir-in-1h25?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CTOR","CTXR","BK4007","BK4139"],"gpt_icon":0},{"id":"2501664206","title":"Citius Pharmaceuticals and Citius Oncology Highlight Lymphir Commercial Launch Planned for First Half of 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2501664206","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501664206?lang=en_us&edition=fundamental","pubTime":"2025-01-07 21:09","pubTimestamp":1736255380,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250107:nFWN3O313O:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CTOR","CTXR","BK4007","BK4139"],"gpt_icon":0},{"id":"2501012832","title":"Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2501012832","media":"PR Newswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501012832?lang=en_us&edition=fundamental","pubTime":"2025-01-07 21:08","pubTimestamp":1736255280,"startTime":"0","endTime":"0","summary":"CRANFORD, N.J., Jan. 7, 2025 /PRNewswire/ -- Citius Pharmaceuticals, Inc.   and its oncology-focused subsidiary, Citius Oncology , today announced significant progress in preparations for the commercial launch of LYMPHIR, an innovative immunotherapy for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma . Management is focused on making LYMPHIR available to patients as quickly as possible, with preparations underway for launch in the first half of 2025.\"Since LYMPHIR's approval in August 2024, we have worked diligently toward supporting its successful launch. We are making significant progress to finalize our manufacturing, marketing, reimbursement and sales efforts. This is a pivotal inflection point as we transition from clinical development to revenue generation. Our strategy not only focuses on a successful U.S. market penetration, but also includes exploring additional growth opportunities, including licensing partnerships in key international markets, f","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/citius-pharmaceuticals-citius-oncology-highlight-130800989.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/citius-pharmaceuticals-citius-oncology-highlight-130800989.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","CLS","BK4113","BK4588","LU2125910500.SGD","BK4539","MF","CTOR","BK4526","BK4585","CTXR","BK4563","BK4145","LU2045819591.USD"],"gpt_icon":0},{"id":"2501884206","title":"Citius Oncology to explore strategic alternatives","url":"https://stock-news.laohu8.com/highlight/detail?id=2501884206","media":"TipRanks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501884206?lang=en_us&edition=fundamental","pubTime":"2025-01-07 20:57","pubTimestamp":1736254648,"startTime":"0","endTime":"0","summary":"Citius Oncology , a majority-owned subsidiary of Citius Pharmaceuticals , announced that it has retained Jefferies  as its exclusive financial advisor to assist in evaluating strategic alternatives aimed at maximizing shareholder value. The engagement of Jefferies underscores Citius Oncology’s commitment to exploring all avenues for enhancing its strategic positioning and advancing its mission to improve patient outcomes in oncology. Strategic alternatives under consideration may include, but are not limited to, partnerships, joint ventures, mergers, acquisitions, licensing or other strategic transactions.Discover outperforming stocks and invest smarter with Top Smart Score Stocks. Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener. American Air upgraded, Nordstrom downgraded: Wall Street’s top analyst calls. Citius Pharmaceuticals upgraded to Buy from Hold at D. Boral Capital. Biotech Alert: Searches spiking for these stocks today. ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/citius-oncology-explore-strategic-alternatives-125728286.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/citius-oncology-explore-strategic-alternatives-125728286.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["JEF","BK4139","BK4007","CTXR","BK4127","CTOR"],"gpt_icon":0},{"id":"2501267825","title":"Sector Update: Health Care Stocks Decline Late Afternoon","url":"https://stock-news.laohu8.com/highlight/detail?id=2501267825","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501267825?lang=en_us&edition=fundamental","pubTime":"2025-01-07 05:02","pubTimestamp":1736197371,"startTime":"0","endTime":"0","summary":"Health care stocks were lower late Monday afternoon, with the NYSE Health Care Index down 0.3% and the Health Care Select Sector SPDR Fund  easing 0.1%.The iShares Biotechnology ETF  added 0.1%.In corporate news, Predictive Oncology  shares surged past 55% after it agreed to be acquired by Renovaro  in an all-stock deal. Renovaro shares popped 10%.Citius Pharmaceuticals'  majority-owned subsidiary Citius Oncology  said it has retained Jefferies as a financial advisor to evaluate possible strategic alternatives. Citius Pharmaceuticals shares were down 2.3% and Citius Oncology jumped 18%.Revance Therapeutics  shares jumped 12%. The company has received a new buyout proposal from Teoxane Laboratories, offering $3.60 per share in cash, topping a bid from Crown Laboratories of $3.10 per share.Regional Health Properties  and SunLink Health Systems  have agreed to merge in an all-stock deal. Regional shares soared 120% and SunLink surged 16%.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4185","BK4007","BK4198","CTOR","BK4581","BK4585","IBB","POAI","RENB","CTXR","LU0053671581.USD","RVNC","SSY","RHE","XLV","BK4588","BK4139","BK4082"],"gpt_icon":0},{"id":"2501234862","title":"Citius Oncology Retains Jeffries to Consider Strategic Alternatives","url":"https://stock-news.laohu8.com/highlight/detail?id=2501234862","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501234862?lang=en_us&edition=fundamental","pubTime":"2025-01-06 21:34","pubTimestamp":1736170468,"startTime":"0","endTime":"0","summary":"Citius Pharmaceuticals'  majority-owned subsidiary Citius Oncology  said it has retained Jefferies as a financial advisor to evaluate possible strategic alternatives.The company said alternatives being considered include partnerships, joint ventures, mergers, acquisitions, or licensing but has no specific timeline for a decision.Citius Oncology Chief Executive Leonard Mazur said the \"goal is to deliver value to shareholders.\"Citius Oncology's main product Lymphir was recently approved by the US Food and Drug Administration for the treatment of relapsed or refractory Stage I-III cutaneous T-cell lymphoma following at least one prior systemic therapy.Citius Oncology shares were up more than 6% and Citius Pharmaceuticals more than 5% in Monday's premarket activity.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","CTXR","CTOR","BK4007"],"gpt_icon":0},{"id":"2501236187","title":"Citius Oncology Engages Jefferies as Exclusive Financial Advisor to Explore Strategic Alternatives","url":"https://stock-news.laohu8.com/highlight/detail?id=2501236187","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501236187?lang=en_us&edition=fundamental","pubTime":"2025-01-06 20:50","pubTimestamp":1736167802,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250106:nTUA99FLMG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BK4139","CTXR","CTOR"],"gpt_icon":0},{"id":"2501968239","title":"Citius Oncology Engages Jefferies as Exclusive Financial Advisor to Explore Strategic Alternatives","url":"https://stock-news.laohu8.com/highlight/detail?id=2501968239","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501968239?lang=en_us&edition=fundamental","pubTime":"2025-01-06 20:50","pubTimestamp":1736167800,"startTime":"0","endTime":"0","summary":"CRANFORD, N.J., Jan. 6, 2025 /PRNewswire/ -- Citius Oncology, Inc.  , a majority-owned subsidiary of Citius Pharmaceuticals, Inc.  , today announced that it has retained Jefferies LLC as its exclusive financial advisor to assist in evaluating strategic alternatives aimed at maximizing shareholder value.The engagement of Jefferies underscores Citius Oncology's commitment to exploring all avenues for enhancing its strategic positioning and advancing its mission to improve patient outcomes in oncology. Strategic alternatives under consideration may include, but are not limited to, partnerships, joint ventures, mergers, acquisitions, licensing or other strategic transactions.Citius Oncology is committed to commercializing LYMPHIR, recently approved by the U.S. Food and Drug Administration  for the treatment of patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma  following at least one prior systemic therapy.In 2021, denileukin diftitox received regulatory approval in","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/citius-oncology-engages-jefferies-exclusive-125000511.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/citius-oncology-engages-jefferies-exclusive-125000511.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","CTXR","CTOR"],"gpt_icon":0},{"id":"2495354622","title":"Citius Pharmaceuticals upgraded to Buy from Hold at D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2495354622","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2495354622?lang=en_us&edition=fundamental","pubTime":"2024-12-30 20:10","pubTimestamp":1735560625,"startTime":"0","endTime":"0","summary":"D. Boral Capital upgraded Citius Pharmaceuticals (CTXR) to Buy from Hold with a $9 price target. Citius owns 90% of Citius Oncology (CTOR), which i...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/citius-pharmaceuticals-upgraded-to-buy-from-hold-at-d-boral-capital?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/citius-pharmaceuticals-upgraded-to-buy-from-hold-at-d-boral-capital?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CTXR","BK4007","BK4139","CTOR"],"gpt_icon":0},{"id":"2495904325","title":"Reported Friday, Citius Oncology FY 2024 GAAP EPS $(0.31) Misses $(0.29) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2495904325","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2495904325?lang=en_us&edition=fundamental","pubTime":"2024-12-30 16:40","pubTimestamp":1735548043,"startTime":"0","endTime":"0","summary":"Citius Oncology (NASDAQ:CTOR) reported quarterly losses of $(0.31) per share which missed the analyst consensus estimate of $(0.29) by 6.9 percent. This is a 63.16 percent decrease over losses of $(0.19) per share from","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/12/42717992/reported-friday-citius-oncology-fy-2024-gaap-eps-0-31-misses-0-29-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Reported Friday, Citius Oncology FY 2024 GAAP EPS $(0.31) Misses $(0.29) Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTOR"],"gpt_icon":0},{"id":"2494355284","title":"BRIEF-Citius Oncology Reports Fiscal Full Year 2024 Financial Results And Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2494355284","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2494355284?lang=en_us&edition=fundamental","pubTime":"2024-12-28 06:05","pubTimestamp":1735337140,"startTime":"0","endTime":"0","summary":"Dec 27 (Reuters) - Citius Oncology Inc   :   * CITIUS ONCOLOGY, INC. REPORTS FISCAL FULL YEAR 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATESource text:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTOR","BK4139"],"gpt_icon":0},{"id":"2494551823","title":"Citius Oncology, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2494551823","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2494551823?lang=en_us&edition=fundamental","pubTime":"2024-12-28 06:00","pubTimestamp":1735336805,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241227:nTUA2HQMV9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CTOR"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":26,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CTOR\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CTOR\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CTOR\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":1,"updateTime":1732939200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/CTOR\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"CTOR","date":"2025-04-21","current":-2.082969,"percent":0.921687,"low":-8.240776,"twenty":-5.142325,"median":-4.012144,"eighty":-3.199072,"high":-1.770477,"avg":-4.161941,"sd":1.414342,"marketCap":48076058},"quantilePoints":[{"date":"2024-08-23","current":-7.506449,"twenty":-8.175502,"median":-7.996,"eighty":-7.800179,"marketCap":131199450},{"date":"2024-08-30","current":-6.464428,"twenty":-8.028637,"median":-7.567643,"eighty":-6.639734,"marketCap":126208166},{"date":"2024-09-06","current":-6.847911,"twenty":-7.922567,"median":-7.149219,"eighty":-6.405992,"marketCap":133695091},{"date":"2024-09-13","current":-5.989639,"twenty":-7.726747,"median":-6.50095,"eighty":-6.274513,"marketCap":116938640},{"date":"2024-09-20","current":-6.099206,"twenty":-7.555404,"median":-6.464428,"eighty":-5.97503,"marketCap":119077761},{"date":"2024-09-27","current":-5.222673,"twenty":-7.472896,"median":-6.354861,"eighty":-5.953117,"marketCap":101964790},{"date":"2024-10-04","current":-4.309619,"twenty":-7.088957,"median":-6.190511,"eighty":-5.617113,"marketCap":84138777},{"date":"2024-10-11","current":-3.542653,"twenty":-6.749301,"median":-6.099206,"eighty":-5.018149,"marketCap":69164927},{"date":"2024-10-18","current":-3.944397,"twenty":-6.661648,"median":-5.953117,"eighty":-4.16353,"marketCap":77008372},{"date":"2024-10-25","current":-4.399098,"twenty":-6.559386,"median":-5.916595,"eighty":-4.331532,"marketCap":85885727},{"date":"2024-10-31","current":-4.419185,"twenty":-6.486341,"median":-5.66094,"eighty":-4.324228,"marketCap":86277899},{"date":"2024-11-08","current":-4.602892,"twenty":-6.464428,"median":-5.16789,"eighty":-4.287705,"marketCap":89864492},{"date":"2024-11-15","current":-3.904222,"twenty":-6.464428,"median":-4.930496,"eighty":-4.287705,"marketCap":76224028},{"date":"2024-11-22","current":-3.564201,"twenty":-6.420601,"median":-4.784407,"eighty":-3.944397,"marketCap":69585621},{"date":"2024-11-29","current":-3.356755,"twenty":-6.347557,"median":-4.693102,"eighty":-3.842134,"marketCap":65535551},{"date":"2024-12-06","current":-5.916595,"twenty":-6.296426,"median":-4.747885,"eighty":-3.776395,"marketCap":115512559},{"date":"2024-12-13","current":-3.907874,"twenty":-6.201468,"median":-4.620605,"eighty":-3.842134,"marketCap":76295332},{"date":"2024-12-20","current":-3.871352,"twenty":-6.164946,"median":-4.528752,"eighty":-3.842134,"marketCap":75582291},{"date":"2024-12-27","current":-3.50613,"twenty":-6.135728,"median":-4.435255,"eighty":-3.725263,"marketCap":68451887},{"date":"2025-01-03","current":-4.012144,"twenty":-6.10651,"median":-4.399098,"eighty":-3.717959,"marketCap":84851818},{"date":"2025-01-10","current":-3.992285,"twenty":-6.033466,"median":-4.399098,"eighty":-3.747177,"marketCap":84431834},{"date":"2025-01-17","current":-4.465946,"twenty":-5.967726,"median":-4.376046,"eighty":-3.723807,"marketCap":94449170},{"date":"2025-01-24","current":-4.296782,"twenty":-5.953117,"median":-4.35308,"eighty":-3.739872,"marketCap":90871550},{"date":"2025-01-31","current":-4.262949,"twenty":-5.953117,"median":-4.346141,"eighty":-3.761786,"marketCap":90156026},{"date":"2025-02-07","current":-4.026118,"twenty":-5.938508,"median":-4.309619,"eighty":-3.767526,"marketCap":85147358},{"date":"2025-02-14","current":-4.330615,"twenty":-5.916595,"median":-4.296782,"eighty":-3.799613,"marketCap":91587074},{"date":"2025-02-21","current":-3.72014,"twenty":-5.901986,"median":-4.296782,"eighty":-3.761786,"marketCap":85862882},{"date":"2025-02-28","current":-3.689139,"twenty":-5.807029,"median":-4.262949,"eighty":-3.720436,"marketCap":85147358},{"date":"2025-03-07","current":-3.162119,"twenty":-5.639027,"median":-4.229116,"eighty":-3.689139,"marketCap":72983450},{"date":"2025-03-14","current":-2.294087,"twenty":-5.507546,"median":-4.152992,"eighty":-3.653403,"marketCap":52948777},{"date":"2025-03-21","current":-1.891071,"twenty":-5.317631,"median":-4.127617,"eighty":-3.617985,"marketCap":43646965},{"date":"2025-03-28","current":-2.030577,"twenty":-5.251891,"median":-4.059951,"eighty":-3.565808,"marketCap":46866823},{"date":"2025-04-04","current":-2.191783,"twenty":-5.220193,"median":-4.053963,"eighty":-3.506186,"marketCap":50587548},{"date":"2025-04-11","current":-1.919282,"twenty":-5.198143,"median":-4.02178,"eighty":-3.38992,"marketCap":44298092},{"date":"2025-04-17","current":-2.002676,"twenty":-5.149629,"median":-4.014793,"eighty":-3.224122,"marketCap":46222851},{"date":"2025-04-21","current":-2.082969,"twenty":-5.142325,"median":-4.012144,"eighty":-3.199072,"marketCap":48076058}],"updateTime":1745320152523}}}